Market Summary
USD557.09+14.39
Delayed2.65%
TMO Alerts
TMO Stock Price
TMO RSI Chart
TMO Valuation
TMO Price/Sales (Trailing)
TMO Profitability
TMO Fundamentals
TMO Revenue
TMO Earnings
Price Action
52 Week Range
475.77618.36
(Low)(High)
Last 7 days
-2.2%
Last 30 days
-5.6%
Last 90 days
-2%
Trailing 12 Months
-1.4%
TMO Financial Health
TMO Investor Care
Peers (Alternatives to Thermo Fisher Scientific)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
TMO | 218.4B | 44.9B | -5.62% | -1.44% | 31.38 | 4.86 | 14.55% | -9.94% |
ILMN | 35.5B | 4.6B | 5.65% | -27.02% | -8.07 | 7.75 | 1.28% | -677.95% |
MTD | 32.5B | 3.9B | -7.42% | 9.05% | 37.3 | 8.3 | 5.43% | 13.46% |
WAT | 18.2B | 3.0B | -10.97% | -4.88% | 25.66 | 6.11 | 6.68% | 2.15% |
BRKR | 10.8B | 2.5B | -3.73% | 16.11% | 36.41 | 4.27 | 4.67% | 7.04% |
| MID-CAP | ||||||||
NEO | 2.4B | 509.7M | 46.19% | 25.15% | -16.73 | 4.74 | 5.24% | -1628.17% |
| SMALL-CAP | ||||||||
PACB | 2.0B | 128.3M | -11.70% | -1.09% | -6.37 | 15.61 | -1.69% | -73.40% |
ADPT | 1.2B | 185.3M | -5.41% | -23.53% | -6 | 6.49 | 20.06% | 3.42% |
QTRX | 450.3M | 105.5M | -12.44% | -50.56% | -4.66 | 4.27 | -4.55% | -67.63% |
BNGO | 341.8M | 27.8M | -23.57% | -31.43% | -2.58 | 12.29 | 54.62% | -83.06% |
CDXS | 271.1M | 138.6M | -29.13% | -76.08% | -8.07 | 1.96 | 32.30% | -57.86% |
CDXC | 121.5M | 72.0M | -9.68% | -16.83% | -7.37 | 1.69 | 6.82% | 39.11% |
HBIO | 117.4M | 113.3M | -15.92% | -55.18% | -12.34 | 1.04 | -4.68% | -3204.17% |
EYPT | 80.8M | 42.4M | -41.42% | -80.17% | -1.03 | 1.9 | 30.40% | -43.67% |
Financials for Thermo Fisher Scientific
| Income Statement (Last 12 Months) | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Revenue | 1.7% | 44,915 | 44,167 | 42,820 | 41,123 | 39,211 |
| S&GA Expenses | 0.2% | 8,993 | 8,972 | 8,768 | 8,458 | 8,007 |
| R&D Expenses | -0.1% | 1,471 | 1,472 | 1,472 | 1,450 | 1,406 |
| Costs and Expenses | 4.1% | 36,522 | 35,097 | 33,182 | 31,323 | 29,183 |
| EBITDA | 0.7% | 9,547 | 9,485 | 9,979 | 10,058 | - |
| EBITDA Margin | -1.0% | 0.21* | 0.21* | 0.23* | 0.24* | - |
| Earnings Before Taxes | -1.1% | 7,835 | 7,920 | 8,496 | 8,628 | 8,841 |
| EBT Margin | -2.7% | 0.17* | 0.18* | 0.20* | 0.21* | - |
| Interest Expenses | 17.5% | 726 | 618 | 573 | 547 | 536 |
| Net Income | -1.2% | 6,960 | 7,045 | 7,450 | 7,611 | 7,728 |
| Net Income Margin | -2.9% | 0.15* | 0.16* | 0.17* | 0.19* | - |
| Free Cahsflow | 23.4% | 6,911 | 5,600 | 6,336 | 7,001 | - |
| Balance Sheet | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Assets | 7.3% | 97,154 | 90,536 | 90,579 | 92,747 | 95,123 |
| Current Assets | 30.7% | 25,229 | 19,299 | 18,100 | 18,776 | 20,113 |
| Cash Equivalents | 192.0% | 8,524 | 2,919 | 1,888 | 2,752 | 4,477 |
| Inventory | -1.5% | 5,634 | 5,722 | 5,668 | 5,483 | 5,051 |
| Net PPE | 7.6% | 9,280 | 8,628 | 8,529 | 8,448 | 8,333 |
| Goodwill | 1.7% | 41,196 | 40,488 | 41,066 | 41,721 | 41,924 |
| Current Liabilities | 53.0% | 17,010 | 11,118 | 10,997 | 12,070 | 13,436 |
| Long Term Debt | 2.7% | 28,909 | 28,150 | 29,250 | 31,389 | 32,333 |
| Shareholder's Equity | 1.0% | 43,978 | 43,549 | 42,354 | 41,018 | 40,793 |
| Retained Earnings | 3.6% | 41,910 | 40,452 | 39,074 | 37,528 | 35,431 |
| Additional Paid-In Capital | 0.9% | 16,743 | 16,596 | 16,467 | 16,292 | 16,174 |
| Shares Outstanding | 0% | 392 | 392 | 392 | - | - |
| Minority Interest | -8.5% | 54.00 | 59.00 | 61.00 | 62.00 | 62.00 |
| Cashflow (Last 12 Months) | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Cashflow From Operations | 12.7% | 9,154 | 8,124 | 8,837 | 9,536 | 9,312 |
| Share Based Compensation | -0.6% | 307 | 309 | 283 | 257 | 230 |
| Cashflow From Investing | 89.4% | -2,159 | -20,326 | -20,397 | -20,604 | -21,932 |
| Cashflow From Financing | -186.0% | -2,810 | 3,266 | 6,457 | 8,286 | 6,581 |
| Dividend Payments | 3.2% | 455 | 441 | 425 | 411 | 395 |
| Buy Backs | 50.0% | 3,000 | 2,000 | 2,000 | 2,000 | 2,000 |
Risks for TMO
What is the probability of a big loss on TMO?
16.1%
Probability that Thermo Fisher Scientific stock will be more than 20% underwater in next one year
0%
Probability that Thermo Fisher Scientific stock will be more than 30% underwater in next one year.
0%
Probability that Thermo Fisher Scientific stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does TMO drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Thermo Fisher Scientific was unfortunately bought at previous high price.
Drawdowns
Returns for TMO
Cumulative Returns on TMO
21.9%
10-Year Cumulative Returns
21.8%
7-Year Cumulative Returns
21.1%
5-Year Cumulative Returns
22.0%
3-Year Cumulative Returns
What are the long-term rolling returns for TMO?
FIve years rolling returns for Thermo Fisher Scientific.
Annualized Returns
Which funds bought or sold TMO recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-03-15 | B. Riley Wealth Advisors, Inc. | reduced | -3.72 | 947,853 | 21,596,900 | 0.60% |
2023-03-10 | BAILLIE GIFFORD & CO | reduced | -4.55 | 24,690,800 | 703,173,000 | 0.73% |
2023-03-10 | MATHER GROUP, LLC. | added | 25.16 | 348,517 | 1,320,520 | 0.03% |
2023-03-10 | VICTORY CAPITAL MANAGEMENT INC | reduced | -6.4 | 2,797,580 | 174,467,000 | 0.19% |
2023-03-08 | Capital Asset Advisory Services LLC | reduced | -4.91 | 103,386 | 2,105,390 | 0.17% |
2023-03-08 | SHEETS SMITH WEALTH MANAGEMENT | unchanged | - | 144,395 | 1,827,400 | 0.29% |
2023-03-07 | Great Lakes Retirement, Inc. | new | - | 626,709 | 626,709 | 0.16% |
2023-03-06 | Rockefeller Capital Management L.P. | reduced | -2.72 | 5,345,000 | 100,453,000 | 0.50% |
2023-03-06 | NORTH STAR ASSET MANAGEMENT INC | reduced | -0.11 | 2,201,530 | 28,235,500 | 1.75% |
2023-03-03 | Crumly & Associates Inc. | reduced | -1.34 | 46,034 | 691,034 | 0.26% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
TMO Alerts
Thermo Fisher Scientific News
Schedule 13G FIlings of Thermo Fisher Scientific
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 09, 2023 | vanguard group inc | 8.30% | 32,534,676 | SC 13G/A | |
| Feb 03, 2023 | blackrock inc. | 7.9% | 30,790,122 | SC 13G/A | |
| Feb 10, 2022 | vanguard group inc | 7.89% | 31,103,788 | SC 13G/A | |
| Feb 01, 2022 | blackrock inc. | 7.9% | 30,982,611 | SC 13G | |
| Feb 10, 2021 | vanguard group inc | 7.82% | 30,997,381 | SC 13G/A | |
| Feb 01, 2021 | blackrock inc. | 7.4% | 29,504,221 | SC 13G/A | |
| Feb 12, 2020 | vanguard group inc | 7.77% | 31,187,697 | SC 13G/A | |
| Feb 06, 2020 | blackrock inc. | 7.0% | 28,202,856 | SC 13G/A |
TMO Fair Value
Thermo Fisher Scientific fair value in different scenarios
The table shows the Fair Value estimates for Thermo Fisher Scientific for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
| Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
|---|---|---|---|---|---|
| Very Low Inflation | - - | - - | - - | - - | - - |
| Current Inflation | 360.84 -35.23% | 467.87 -16.02% | 662.22 18.87% | 962.67 72.80% | 1245.53 123.58% |
| Very High Inflation | - - | - - | - - | - - | - - |
Historical Thermo Fisher Scientific Fair Value Estimates
Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price
Recent SEC filings of Thermo Fisher Scientific
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Mar 15, 2023 | 4 | Insider Trading | |
| Mar 14, 2023 | 144 | Notice of Insider Sale Intent | |
| Mar 13, 2023 | 144 | Notice of Insider Sale Intent | |
| Mar 07, 2023 | 4 | Insider Trading | |
| Mar 07, 2023 | 4 | Insider Trading | |
| Mar 02, 2023 | 4 | Insider Trading | |
| Mar 02, 2023 | 4 | Insider Trading | |
| Mar 02, 2023 | 4 | Insider Trading | |
| Mar 02, 2023 | 4 | Insider Trading | |
| Mar 02, 2023 | 4 | Insider Trading |
Latest Insider Trading transactions for TMO
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-03-14 | CASPER MARC N | sold | -4,153,450 | 553 | -7,500 | chairman & ceo |
2023-03-13 | CASPER MARC N | sold | -4,083,690 | 544 | -7,500 | chairman & ceo |
2023-03-05 | Lagarde Michel | sold (taxes) | -73,286 | 559 | -131 | executive vice president & coo |
2023-03-05 | Pettiti Gianluca | sold (taxes) | -36,923 | 559 | -66.00 | executive vice president |
2023-02-28 | Williamson Stephen | sold (taxes) | -452,370 | 541 | -835 | sr. vp and cfo |
2023-02-28 | Pettiti Gianluca | sold (taxes) | -420,948 | 541 | -777 | executive vice president |
2023-02-28 | CASPER MARC N | sold (taxes) | -1,445,960 | 541 | -2,669 | chairman & ceo |
2023-02-28 | Boxer Michael A | sold (taxes) | -120,812 | 541 | -223 | svp and general counsel |
2023-02-28 | Holmes Joseph R. | sold (taxes) | -21,128 | 541 | -39.00 | vp & chief accounting officer |
2023-02-28 | Lagarde Michel | sold (taxes) | -552,053 | 541 | -1,019 | executive vice president & coo |
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
TMO Income Statement
2022-12-31Consolidated Statement of Income - USD ($) shares in Millions, $ in Millions | 12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
| Revenues | |||
| Revenues | $ 44,915 | $ 39,211 | $ 32,218 |
| Costs and operating expenses: | |||
| Selling, general and administrative expenses | 8,993 | 8,007 | 6,930 |
| Research and development expenses | 1,471 | 1,406 | 1,181 |
| Restructuring and other costs | 114 | 197 | 99 |
| Total costs and operating expenses | 36,522 | 29,183 | 24,424 |
| Operating income | 8,393 | 10,028 | 7,794 |
| Interest income | 272 | 43 | 65 |
| Interest expense | (726) | (536) | (553) |
| Other income/(expense) | (104) | (694) | (76) |
| Income before income taxes | 7,835 | 8,841 | 7,230 |
| Provision for income taxes | (703) | (1,109) | (850) |
| Equity in earnings/(losses) of unconsolidated entities | (172) | (4) | (3) |
| Net income | 6,960 | 7,728 | 6,377 |
| Less: net income attributable to noncontrolling interests and redeemable noncontrolling interest | 10 | 3 | 2 |
| Net income attributable to Thermo Fisher Scientific Inc. | $ 6,950 | $ 7,725 | $ 6,375 |
| Earnings per share attributable to Thermo Fisher Scientific Inc. | |||
| Basic (in dollars per share) | $ 17.75 | $ 19.62 | $ 16.09 |
| Diluted (in dollars per share) | $ 17.63 | $ 19.46 | $ 15.96 |
| Weighted average shares | |||
| Basic (in shares) | 392 | 394 | 396 |
| Diluted (in shares) | 394 | 397 | 399 |
| Product revenues | |||
| Revenues | |||
| Revenues | $ 28,548 | $ 30,361 | $ 25,306 |
| Costs and operating expenses: | |||
| Cost of revenues | 14,247 | 13,594 | 11,407 |
| Service revenues | |||
| Revenues | |||
| Revenues | 16,367 | 8,850 | 6,912 |
| Costs and operating expenses: | |||
| Cost of revenues | $ 11,697 | $ 5,979 | $ 4,807 |
TMO Balance Sheet
2022-12-31Consolidated Balance Sheet - USD ($) $ in Millions | Dec. 31, 2022 | Dec. 31, 2021 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 8,524 | $ 4,477 |
| Accounts receivable, less allowances of $189 and $150 | 8,115 | 7,977 |
| Inventories | 5,634 | 5,051 |
| Contract assets, net | 1,312 | 968 |
| Other current assets | 1,644 | 1,640 |
| Total current assets | 25,229 | 20,113 |
| Property, plant and equipment, net | 9,280 | 8,333 |
| Acquisition-related intangible assets, net | 17,442 | 20,113 |
| Other assets | 4,007 | 4,640 |
| Goodwill | 41,196 | 41,924 |
| Total assets | 97,154 | 95,123 |
| Current liabilities: | ||
| Short-term obligations and current maturities of long-term obligations | 5,579 | 2,537 |
| Accounts payable | 3,381 | 2,867 |
| Accrued payroll and employee benefits | 2,095 | 2,427 |
| Contract liabilities | 2,601 | 2,655 |
| Other accrued expenses | 3,354 | 2,950 |
| Total current liabilities | 17,010 | 13,436 |
| Deferred income taxes | 2,849 | 3,837 |
| Other long-term liabilities | 4,238 | 4,540 |
| Long-term obligations | 28,909 | 32,333 |
| Commitments and Contingencies | ||
| Redeemable noncontrolling interest | 116 | 122 |
| Thermo Fisher Scientific Inc. shareholders’ equity: | ||
| Preferred stock, $100 par value, 50,000 shares authorized; none issued | ||
| Common stock, $1 par value, 1,200,000,000 shares authorized; 440,668,112 and 439,154,741 shares issued | 441 | 439 |
| Capital in excess of par value | 16,743 | 16,174 |
| Retained earnings | 41,910 | 35,431 |
| Treasury stock at cost, 50,157,275 and 44,720,112 shares | (12,017) | (8,922) |
| Accumulated other comprehensive items | (3,099) | (2,329) |
| Total Thermo Fisher Scientific Inc. shareholders’ equity | 43,978 | 40,793 |
| Noncontrolling interests | 54 | 62 |
| Total equity | 44,032 | 40,855 |
| Total liabilities, redeemable noncontrolling interest and equity | $ 97,154 | $ 95,123 |